Interestingly, FGFR3-altered tumours showed concomitant PI3KCA/RAS alterations in 26.2% of UTUC patients and 26.5% of BUC patients. This evidence concerns the gene FGFR3 and renal pelvis/ureter urothelial carcinoma.